Annual report pursuant to Section 13 and 15(d)

Discontinued Operations - Schedule of Discontinued Operation of Balance Sheet and Operation Statement (Details)

v3.21.1
Discontinued Operations - Schedule of Discontinued Operation of Balance Sheet and Operation Statement (Details) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash $ 31,430 $ 17,767
Accounts receivable, net 151,363 482,472
Prepaid expenses and other current assets 1,717 5,150
Current assets classified as held for sale 184,510 505,389
Property and equipment, net 685 3,354
Deposits 100,014 106,043
Right of use assets 100,116 185,842
Non-current assets classified as held for sale 200,815 295,239
Accounts payable 1,911,378 2,041,628
Accrued expenses 1,642,950 1,714,789
Current portion of right-of-use operating lease obligations 91,166 85,726
Current portion of notes payable 168,751 256,274
Current liabilities classified as held for sale 3,814,245 4,098,417
Note payable 1,196,256
Right-of-use operating lease liability 1,000,272 100,116
Liabilities classified as held for sale 78,217 100,116
Revenue from services 529,066 1,095,048
Cost of services 5,536 236,187
Gross profit 523,530 858,861
Operating expenses 1,184,226 104,615
Other expense, net 35,371 31,374
Provision for income taxes
Loss from discontinued operations (696,067) (1,450,869)
Advanced Molecular Services Group and Health Technology Solutions, Inc [Member]    
Cash 31,294 16,667
Accounts receivable, net 151,363 482,472
Prepaid expenses and other current assets 1,717 5,150
Current assets classified as held for sale 184,374 504,289
Property and equipment, net 685 3,354
Deposits 6,029
Right of use assets
Non-current assets classified as held for sale 685 9,383
Accounts payable 726,220 805,652
Accrued expenses 1,308,283 1,350,106
Current portion of right-of-use operating lease obligations
Current portion of notes payable 168,751 256,274
Current liabilities classified as held for sale 2,203,254 2,412,032
Note payable 69,267
Right-of-use operating lease liability
Liabilities classified as held for sale 69,267
Revenue from services [1] 528,624 1,109,135
Cost of services 5,536 150,205
Gross profit 523,088 958,930
Operating expenses 1,045,410 1,615,477
Other expense, net 84,129 62,771
Provision for income taxes
Loss from discontinued operations (606,451) (719,318)
EPIC Reference Labs, Inc. [Member]    
Cash 136 1,100
Accounts receivable, net
Prepaid expenses and other current assets
Current assets classified as held for sale 136 1,100
Property and equipment, net
Deposits 100,014 100,014
Right of use assets 100,116 185,842
Non-current assets classified as held for sale 200,130 285,856
Accounts payable 1,185,158 1,235,976
Accrued expenses 334,667 364,683
Current portion of right-of-use operating lease obligations 91,166 85,726
Current portion of notes payable
Current liabilities classified as held for sale 1,198,614 1,686,385
Note payable
Right-of-use operating lease liability 8,950 100,116
Liabilities classified as held for sale 8,950 100,116
Revenue from services [2] 442 (14,087)
Cost of services 85,982
Gross profit 442 (100,069)
Operating expenses 138,816 453,280
Other expense, net (48,758) 41,844
Provision for income taxes
Loss from discontinued operations $ (89,616) $ (731,551)
[1] Revenue from services, includes related party revenue of $___ million and $0.4 million, respectively.
[2] The Company recorded bad debts in excess of gross revenues in the three months ended September 30, 2019.